AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01605526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5045337
Description: Multiple escalating oral doses, Days 1-5 (1-3) of each 28-day cycle, up to 6 cycles
Study NCT01605526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: 60 mg/m2 (75 mg/m2, 50 mg/m2) iv on Day 1 of each 28-day cycle, up to 6 cycles
Study NCT03464994 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: ophthalmological examination
Description: * Refraction~* Best corrected visual acuity~* Intraocular pressure~* Slit lamp examination with vital dye (Oxford grading)~* Tear break-up time (TBUT)~* Schirmer I testing~* Specular (TMS-4 Tomey) and elevation (pentacam Oculus and Orbscan Bausch \& Lomb) corneal videotopographies~* Pachymetry~* Questionnaires: Ocular surface disease index, quality of vision (visual analogic scale), and quality of life (NEI-VFQ25)~* questionnaire about ichthyosis severity~* questionnaire about life quality specifically for patient presenting ichthyosis
Study NCT01841944 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pikasol
Description: Pikasol®, 3 capsules (1.8 g EPA+DHA)/day
Study NCT01841944 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Corn oil
Description: Corn oil (56% linoleic acid, 32% oleic acid, 10% palmitic acid), unchanged and according to the manufacturer
Study NCT01765322 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ZILOS-TK IVOS Analyzer
Description: The subjects are going to participate the treatment of assisted hatching in vitro fertilization by Zona Infrared Laser Optical System (ZILOS-TK,Hamilton Thorne Biosciences,USA)
Study NCT04270955 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Embolization of the Middle Meningeal Artery
Description: Using established endovascular techniques and materials patient will have a diagnostic catheter based angiogram performed on the side(s) of the brain where the subdural hematoma is present. After verifying the vascular anatomy to ensure safety of the procedure the Middle Meningeal Artery will be embolized.
Study NCT01560000 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Dietary fiber
Description: Wheat, barley, oat and bran fibers added to a breakfast product
Study NCT03332602 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: free FeSO4
Description: Testmeal with free FeSO4
Study NCT01964820 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Affect Skills Training
Description: Our intervention teaches 8 skills that research suggests lead to increased positive emotions, beginning with basic skills (recognizing and savoring positive events), and progressing to more complex ones such as goal- setting and acts of kindness. Established skills such as reappraising negative thoughts are also taught, in the context of cultivating positive emotions and coping with stress.~The skills are taught over 5 weeks, with one or more new skills introduced each week. A week consists of 1-2 days of didactic material and 5-6 days of real-life skills practice and reporting.~For a full description, see A positive affect intervention for people experiencing health-related stress: development and non-randomized pilot test (Moskowitz et al., 2012).
Study NCT04270955 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care including possible surgical evacuation of subdural hematoma
Description: Standard of care could include observation or intervention including surgical drainage of subdural hematoma by bedside drain, Subdural Evacuating Port System (SEPS), burr hole or craniotomy
Study NCT03332602 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: free FeSO4 and empty microspheres
Description: Testmeal with free FeSO4 and empty micropsheres
Study NCT03332602 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: free FeSO4 and hylauronic acid
Description: Testmeal with free FeSO4 and hyaluronic acid
Study NCT04285619 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positive expectation
Description: After heating, the physiotherapist will apply the bandage with flossing on both ankles, using 2 Voodoo Floss Bands (Power Guidance model). The distal to proximal bandage will begin with a tension of 50-70% and each lap of the bandage will cover 50% of the previous lap. There will be 3 figures of 8 that will cover the hindfoot and the distal third of the leg.~With the bandage applied on both feet, the runners will perform plantar flexion and active dorsal flexion movements in a range of complete joint movement with both ankles, at a constant rate of 2 seconds of plantar flexion, followed by another 2 of dorsal flexion, during A period of 2 minutes. Next, the therapist will remove the bandages and the athlete will walk barefoot for a minute, to restore normal blood flow.~During the first application of the bandage, the investigator will induce the positive expectation through a standardized phrase for all subjects
Study NCT03332602 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: free FeSO4 and eudragit polymer
Description: Testmeal with free FeSO4 and eudragit polymer
Study NCT03332602 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: encapsulated FeSO4 3.2%
Description: Testmeal with encapsulated FeSO4 with 3.2% Fe loading
Study NCT03332602 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: encapsulated FeSO4 20%
Description: Testmeal with encapsulated FeSO4 with 20% Fe loading
Study NCT03332602 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: encapsulated FeSO4 3.2%, encapsulated Vitamin A
Description: Testmeal with encapsulated FeSO4 with 3.2% Fe loading, and encapsulated Vitamin A
Study NCT04285619 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neutral expectation
Description: After heating, the physiotherapist will apply the bandage with flossing on both ankles, using 2 Voodoo Floss Bands (Power Guidance model). The distal to proximal bandage will begin with a tension of 50-70% and each lap of the bandage will cover 50% of the previous lap. There will be 3 figures of 8 that will cover the hindfoot and the distal third of the leg.~With the bandage applied on both feet, the runners will perform plantar flexion and active dorsal flexion movements in a range of complete joint movement with both ankles, at a constant rate of 2 seconds of plantar flexion, followed by another 2 of dorsal flexion, during A period of 2 minutes. Next, the therapist will remove the bandages and the athlete will walk barefoot for a minute, to restore normal blood flow.~During the first application of the bandage, the researcher will not induce any expectations to the athletes.
Study NCT03332602 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: encapsulated FeSO4 3.2%, encapsulated Vitamin A, free Folic Acid
Description: Testmeal with encapsulated FeSO4 with 3.2% Fe loading, and encapsulated Vitamin A, with free folic acid.
Study NCT04270955 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard of care including possible surgical evacuation of subdural hematoma
Description: Standard of care could include observation or intervention including surgical drainage of subdural hematoma by bedside drain, Subdural Evacuating Port System (SEPS), burr hole or craniotomy
Study NCT03332602 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FeSO4 embedded in Hyaluronic acid
Description: Testmeal with FeSO4 embedded in Hyaluronic acid
Study NCT02125227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin, Metformin, YH14755
Description: single dose
Study NCT02125227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH14755
Description: single dose
Study NCT01798589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethylenediamine dihydrochloride allergen patch
Description: 1 allergen panel containing 2 allergen and 2 control patches
Study NCT00582140 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pTVG-HP with rhGM-CSF
Description: pTVG-HP (dose 1: 100 μg) with rhGM-CSF (200 μg); administered i.d. biweekly for 6 total doses
Study NCT00582140 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pTVG-HP with rhGM-CSF
Description: pTVG-HP (dose 2: 500 μg) with rhGM-CSF (200 μg); administered i.d. biweekly for 6 total doses
Study NCT01915836 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: web-based video game (Quit IT)
Study NCT00582140 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pTVG-HP with rhGM-CSF
Description: pTVG-HP (dose 3: 1,500 μg) with rhGM-CSF (200 μg); administered i.d. biweekly for 6 total doses
Study NCT03239366 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BioK+ 100% probiotic
Description: The active BioK+ product will include the 3 strains of Lactobacillus: L. acidophilus CL1285®, L. casei LBC80R® and L. rhamnosus CLR2®, representing the bacteria found in Bio-K+ probiotic capsules 50B®;
Study NCT03239366 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo product will NOT include the 3 strains of Lactobacillus: L. acidophilus CL1285®, L. casei LBC80R® and L. rhamnosus CLR2®, representing the bacteria found in Bio-K+ probiotic capsules 50B®;
Study NCT01553630 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RIA bone graft
Description: Acute autogenous bone grafting with RIA graft at the time of surgical fixation.
Study NCT01553630 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery without bone graft
Description: Plating of fracture without bone graft
Study NCT04043546 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aerobic+resistance exercise training program
Description: Personalized exercise program based on the inclusion testing and patient screening will be provided to the patient. The program will consist of a gradual walking program as well as a gradual resistance training program using therabands.
Study NCT04870242 — intervention group
Intervention type: OTHER
Intervention: Observational study, non-interventional
Description: observational study for the ERAS protocols in pediatric surgery
Study NCT02372474 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem cell
Description: Out of 112 high risk patients for POF diagnosis was established in 10 cases. Endometrial fractional biopsy was taken, stained with H\&E stain and by Immunohistochemical (IH) staining by stem cell marker OCT4. IH expression of stem cell was evaluated before and after transplantation according to Edessy Stem Cell Scoring (ESS). After laparoscopic injection of stem cell sample in the ovaries, participants were followed up monthly for a period of one year by hormonal (FSH, LH and E2), clinical (resuming menstruation and pregnancy), US (folliculometry), histopathological (HP), and IH expression of stem cell (stem cell positivity and scoring according to ESS).
Study NCT01682135 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Administered IV.
Study NCT02530528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHG
Description: Varied application times
Study NCT02530528 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHG
Description: Varied application times
Study NCT03729674 — intervention group
Intervention type: DRUG
Intervention: Biosimilar
Description: Biologic-naïve patients starting any biosimilar; patients switching to biosimilar from an alternative biologic therapy; or patients switching to a biosimilar after successfully completing and exiting a previous course of therapy with the equivalent originator drug.
Study NCT03729674 — intervention group
Intervention type: DRUG
Intervention: Originator (legacy) drug
Description: Biologic-naïve patients starting any originator (legacy) drug; patients switching to an originator drug from an alternative biologic therapy; or patients starting a new cycle with the originator drug.
Study NCT01202331 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: mass treatment with oral azithromycin
Description: For baseline and follow-up surveys prior to azithromycin distribution, a stratified random sample from two age groups will be chosen: 1) 60 study participants younger than 10 years old and 2) 60 study participants aged 10 years and above. Clinical examination will be performed and conjunctival swabs will be taken from all the study participants. Nasopharyngeal swabs will be collected in each community from 15 randomly selected children among the 60 participants under age 10 who were recruited for conjunctival swabbing. Then a single dose of azithromycin will be distributed according to study design: in tablet form for adults; a weight-adjusted tablet dose for children ages 8-10; and pediatric suspension for children ages 1 - 7.
Study NCT01202331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mass treatment with oral azithromycin
Description: For baseline and follow-up surveys prior to azithromycin distribution, a stratified random sample from two age groups will be chosen: 1) 60 study participants younger than 10 years old and 2) 60 study participants aged 10 years and above. Clinical examination will be performed and conjunctival swabs will be taken from all the study participants. Nasopharyngeal swabs will be collected in each community from 15 randomly selected children among the 60 participants under age 10 who were recruited for conjunctival swabbing. Then a single dose of azithromycin will be distributed according to study design: in tablet form for adults; a weight-adjusted tablet dose for children ages 8-10; and pediatric suspension for children ages 1 - 7.
Study NCT02474433 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol (Cytotec)
Study NCT01705600 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain Verbalization Repression Rules
Description: The involved subjects will be randomized to either a bracelet with receive verbal repression guidelines OR just a bracelet. They will receive typical physical therapy interventions for the treatment of low back pain (modalities, exercise, manual treatment) with the only change being the education of the one group to repress verblization of pain complaints. The bracelet is worn as a reminder of the rules given.
Study NCT01617460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Flexibly dose administered orally once daily
Study NCT03053297 — intervention group
Intervention type: OTHER
Intervention: Patient Reported Outcomes
Description: HRQoL will be assessed using questionnaire EORTC QLQ-C30 and the questionnaire EORTC QLQ-LC 13.~These two questionnaires are validated instruments, translated in various languages and are not used as an intervention but rather to track patient quality of life and symptom reduction in real-life settings. Data for these patient reported outcomes will be collected prospectively from the time of enrolment until the end of follow-up. The two questionnaires will be self-administered by the patients in both cohorts at the enrolment visit and subsequently every 3 months (±1 month) at routine standard of care scheduled visits. The questionnaires are expected to take about 15 minutes to complete
Study NCT04359303 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systemic indirect endovenous ozone therapy
Description: 200 mL at 40 mcg/mL of medical ozone / oxygen in 200 mL of patients blood mixed in an homologated device for the procedure.
Study NCT03854708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 pmol/kg*min pancreatic polypeptide
Description: PP 3 pmol/kg\*min was intravenously infused 30 minutes before the meal until the end of the meal. For this purpose, a cannula was inserted into the subjects' forearm vein. Human PP (CS Bio, Menlo Park, USA) was dissolved in a 0.9 % saline solution containing 5 % albumin to reduce absorption of PP to the syringe and tubing.
Study NCT03854708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 pmol/kg*min pancreatic polypeptide
Description: PP 10 pmol/kg\*min was intravenously infused 30 minutes before the meal until the end of the meal. For this purpose, a cannula was inserted into the subjects' forearm vein. Human PP (CS Bio, Menlo Park, USA) was dissolved in a 0.9 % saline solution containing 5 % albumin to reduce absorption of PP to the syringe and tubing.
Study NCT03854708 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (saline solution) was intravenously infused 30 minutes before the meal until the end of the meal. For this purpose, a cannula was inserted into the subjects' forearm vein. The placebo consists of a 0.9 % saline solution containing 5 % albumin.
Study NCT04392518 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: Breathing, posture, dynamic core stabilization, upper and lower extremity strengthening exercises.
Study NCT01055158 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-based CBT
Description: A form of CBT delivered over the telephone by a trained, licensed, master's or doctoral level clinician. The intervention consists of approximately 10 sessions conducted over approximately 14 weeks. Each session is approximately 30 to 50 minutes. All sessions begin with a depression rating and agenda setting and end with task assignments and summaries.
Study NCT01055158 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Participants randomized to this condition will be referred to receive in-person psychotherapy. Research study staff will help participants to set up their first appointment with a psychotherapist.
Study NCT03610061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: All patients will receive:~Day 1-Day 5: External Beam Radiotherapy to target site(s)-daily for 5 days (i.e. 5 fractions).~D2: Commence durvalumab. Continue 4-weekly until disease progression. Patients can continue until a second radiological progression if clinical benefit is ongoing.
Study NCT03610061 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: All patients will receive:~Day 1-Day 5: External Beam Radiotherapy to target site(s)-daily for 5 days (i.e. 5 fractions).~D2: Commence durvalumab. Continue 4-weekly until disease progression. Patients can continue until a second radiological progression if clinical benefit is ongoing.
Study NCT03610061 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy (cohort 6 only)
Description: Cohort 6 patients (only) will receive:~Day 8-Day 10: External Beam Radiotherapy to target site(s)- daily (ie. 5 further fractions to a total of 10 fractions)
Study NCT05618665 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Asthma Education
Description: Asthma education about asthma disease, its symptoms, diagnosis, treatment, risk factors, use of medication, use of medication apparatus, vaccination treatment, follow-up of the asthmatic child, precautions to be taken in prevention, what to do during an attack, what to do for adaptation to the disease and things to do in school life.
Study NCT05618665 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Delivery of booklets
Description: The booklets, prepared by the researchers, included information about the content of the education.
Study NCT01915836 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Study NCT01915836 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evaluation Interview
Study NCT04594590 — intervention group
Intervention type: GENETIC
Intervention: Mutation analysis
Description: The investigators will sequence DNA samples from the patients or their families.
Study NCT03171220 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neoantigen Reactive T Cells(NRTs)
Description: Neoantigen Reactive T Cells in an expected volume of 100 milliliter（mL） will be given by intravenous injection over 2-10 minutes through either a peripheral or a central line.
Study NCT03171220 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: SHR-1210 200mg will be administered as an intravenous infusion over 60 minutes.
Study NCT03171220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine(FLU) 30mg/m2/d×3d，3 days prior to each NRTs infusion as preconditional chemotherapy.
Study NCT03171220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide(CTX) 300mg/m2/d×3d，3 days prior to each NRTs infusion as preconditional chemotherapy.
Study NCT03171220 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Interleukin-2(IL-2)will be continuous intravenous infused since the first day of the cell infusion for 5 consecutive days, 4000,000 international unit per day.
Study NCT03620786 — intervention group
Intervention type: DEVICE
Intervention: Sonablate HIFU device
Description: In this study, we will be using the Sonablate 450 HIFU System. The Sonablate HIFU device was approved by the U.S. FDA for prostate tissue ablation in October, 2015. HIFU is an example of focal therapy, where the intervention involves targeting diseased areas of prostate tissue, while preserving healthy prostate tissue and minimizing damage to surrounding structures.
Study NCT00554216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VI-0521
Description: 3.75 mg phentermine/23 mg topiramate
Study NCT00554216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VI-0521
Description: 15 mg phentermine/92 mg topiramate
Study NCT00554216 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matched phentermine/topiramate
Description: Placebo matched phentermine/topiramate
Study NCT00143715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phytonadione (Vitamin K1)
Description: 1.25 mg given orally